MX9701860A - Suministro intracelular de agentes quimicos, a un tipo especifico de celula. - Google Patents

Suministro intracelular de agentes quimicos, a un tipo especifico de celula.

Info

Publication number
MX9701860A
MX9701860A MX9701860A MX9701860A MX9701860A MX 9701860 A MX9701860 A MX 9701860A MX 9701860 A MX9701860 A MX 9701860A MX 9701860 A MX9701860 A MX 9701860A MX 9701860 A MX9701860 A MX 9701860A
Authority
MX
Mexico
Prior art keywords
composition
chemical agent
cbel
intracellular delivery
chemical agents
Prior art date
Application number
MX9701860A
Other languages
English (en)
Other versions
MXPA97001860A (es
Inventor
Prakash Ramesh K
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of MXPA97001860A publication Critical patent/MXPA97001860A/es
Publication of MX9701860A publication Critical patent/MX9701860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Una composicion para suministro intracelular específico de un agente químico en una célula portadora del receptor CR2 que comprende una ligazon del receptor CR2 y un grupo coordinador que induce la endocitosis (CBEL) acoplado ala gente químico. El CBEL se liga al receptor CR2 y permite la endocitosis de la composicion. Opcionalmente, la composicion puede incluir un separador que puede ser ya sea biodegradable o no biodegradable para acoplar el CBEL al agente químico. Los agentes químicos pueden incluir citotoxinas, ácidos nucleicos de transformacion, reguladores de gen, radiactivadores, antígenos, drogas y semejantes. La composicion puede comprender además un portador tal como un polímero soluble en agua, una liposoma o un material en partículas. Los métodos para usar estas composiciones para suministrar un agente químico in vivo o in vitro también se dan a conocer.
MX9701860A 1994-09-13 1995-09-12 Suministro intracelular de agentes quimicos, a un tipo especifico de celula. MX9701860A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
US305770 1994-09-13
PCT/US1995/011515 WO1996008263A1 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type

Publications (2)

Publication Number Publication Date
MXPA97001860A MXPA97001860A (es) 1997-06-01
MX9701860A true MX9701860A (es) 1997-06-28

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701860A MX9701860A (es) 1994-09-13 1995-09-12 Suministro intracelular de agentes quimicos, a un tipo especifico de celula.

Country Status (13)

Country Link
EP (1) EP0781139A1 (es)
JP (1) JPH10505835A (es)
KR (1) KR970705404A (es)
CN (1) CN1157570A (es)
AU (1) AU697469B2 (es)
BR (1) BR9508951A (es)
CA (1) CA2198361A1 (es)
CZ (1) CZ74797A3 (es)
HU (1) HUT77263A (es)
MX (1) MX9701860A (es)
PL (1) PL319100A1 (es)
WO (1) WO1996008263A1 (es)
ZA (1) ZA957688B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
CA2299368A1 (en) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
ATE459340T1 (de) * 1997-11-19 2010-03-15 Univ Georgetown Zielgerichtete liposomen zur verabreichung von genen
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Also Published As

Publication number Publication date
KR970705404A (ko) 1997-10-09
ZA957688B (en) 1996-05-13
BR9508951A (pt) 1999-04-06
JPH10505835A (ja) 1998-06-09
CA2198361A1 (en) 1996-03-21
CZ74797A3 (en) 1997-08-13
AU697469B2 (en) 1998-10-08
AU3550795A (en) 1996-03-29
WO1996008263A1 (en) 1996-03-21
CN1157570A (zh) 1997-08-20
PL319100A1 (en) 1997-07-21
HUT77263A (hu) 1998-03-02
EP0781139A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
WO2000007543A3 (en) Conjugates targeted to the interleukin-2 receptors
WO1992020316A3 (en) Targeted delivery of genes encoding immunogenic proteins
Zenke et al. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells.
Kircheis et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery
Zhou et al. Lipophilic polylysines mediate efficient DNA transfection in mammalian cells
AU5580896A (en) Targeted delivery of genes encoding secretory proteins
AU3876695A (en) Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
AU637085B2 (en) New transferrin-polycation conjugates
AU2063197A (en) Materials and methods for enhancing cellular internalization
EP0757099A3 (en) CTLA4 mutant molecules and uses thereof
SG50630A1 (en) Method for delivering nucleic acid into cells
WO2000015231A8 (en) Adenosine a3 receptor modulators
ES2171167T3 (es) Adenovirus para el transporte de adn extraño en celulas eucarioticas superiores.
IL142905A0 (en) Functional antagonists of hedgehog activity
MX9701860A (es) Suministro intracelular de agentes quimicos, a un tipo especifico de celula.
Kato et al. Targeted delivery of peptides, proteins, and genes by receptor-mediated endocytosis
WO2001004334A3 (en) Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 coxsacki adenovirus receptor (car)
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
PT1009817E (pt) Receptor de rtd
Wojda et al. Surface membrane biotinylation efficiently mediates the endocytosis of avidin bioconjugates into nucleated cells
BR9711081A (pt) Direcionamento de pró-drogas macromoleculares para linfócitos t.
WO1999007324A3 (en) Conjugates targeted to the interleukin-2 receptor
Guillaudeux et al. In situ hybridization localizes the human OTF3 to chromosome 6p21. 3→ p22 and OTF3L to 12p13
WO2001060848A3 (en) Conjugates targeted to target receptors
AU8818398A (en) Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent